Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation

Cell Cycle

Volumn 11, Issue 14, 2012, Pages 2699-2710

  Casaburi, Ivan ^a   Avena, Paola ^a   Lanzino, Marilena ^a   Sisci, Diego ^a   Giordano, Francesca ^a   Maris, Pamela ^a   Catalano, Stefania ^a   Morelli, Catia ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Bile acid; Cyclin D1; Endometrial cancer; Obesity; TGR5

Indexed keywords

CHENODEOXYCHOLIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; TGR5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTAGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84864383668     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21029     Document Type: Article

References (37)

1. Cancer Research UK. CancerStats: corpus uteri cancer. http://info.cancerresearchuk.or/cancerstats/(9 March 2012, date last accessed).
2. Madison T, Schottenfeld D, James SA, Schwartz AG, Gruber SB. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment and survival. Am J Public Health 2004; 94:2104-11; PMID:15569961; http://dx.doi.org/10.2105/AJPH.94.12.2104.
3. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002; 360:861-8; PMID:12243933; http://dx.doi.org/10.1016/S0140- 6736(02)09958-0.
4. Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology and pathophysiology. World J Gastroenterol 2009; 15:804-16; PMID:19230041; http://dx.doi.org/10.3748/wjg.15.804.
5. Engelking LR, Dasher CA, Hirschowitz BI. Withinday fluctuations in serum bile-acid concentrations among normal control subjects and patients with hepatic disease. Am J Clin Pathol 1980; 73:196-201; PMID:7188830.
6. Everson GT. Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry. J Lipid Res 1987; 28:238-52; PMID:3553403.
7. Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM. The role of bile acids in carcinogenesis. Mutat Res 2001; 480-481:359-69; PMID:11506828; http://dx.doi.org/10.1016/S0027-5107(01)00195-6.
8. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284:1362-5; PMID:10334992; http://dx.doi.org/10.1126/science.284.5418.1362.
9. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284:1365-8; PMID:10334993; http://dx.doi.org/10.1126/science.284.5418.1365.
10. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3:543-53; PMID:10360171; http://dx.doi.org/10.1016/S1097-2765(00)80348-2.
11. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298:714-9; PMID:12419312; http://dx.doi.org/10.1016/S0006- 291X(02)02550-0.
12. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278:9435-40; PMID:12524422; http://dx.doi.org/10.1074/jbc.M209706200.
13. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31:111-8; PMID:9770722; http://dx.doi.org/10.1080/01635589809514689.
14. Goldberg AA, Beach A, Davies GF, Harkness TA, Leblanc A, Titorenko VI. Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget 2011; 2:761-82; PMID:21992775.
15. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994; 9:707-18; PMID:8108113.
16. Nikaido T, Li SF, Shiozawa T, Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996; 78:1248-53; PMID:8826947; http://dx.doi.org/10.1002/(SICI)1097-0142(19960915)78: 6〈1248::AIDCNCR12〉3.0.CO;2-0.
17. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-47; PMID:15331580; http://dx.doi.org/10.1210/en.2004-0959.
18. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 2007; 213:589-602; PMID:17786953; http://dx.doi.org/ 10.1002/jcp.21246.
19. Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, Leslie KK. EGFR isoforms and gene regulation in human endometrial cancer cells. Mol Cancer 2010; 9:166; PMID:20579378; http://dx.doi.org/10.1186/1476-4598-9-166.
20. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17:328-36; PMID:16956771; http://dx.doi.org/10.1016/j.tem.2006.08.006.
21. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579-91; PMID:15286738; http://dx.doi.org/10.1038/nrc1408.
22. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366:491-505; PMID:16084259; http://dx.doi.org/10.1016/S0140-6736(05)67063-8.
23. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-67; PMID:22267462.
24. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009; 50:120-5; PMID:18815433; http://dx.doi.org/10. 1194/jlr.R800026-JLR200.
25. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006; 25:1419-25; PMID:16541101; http://dx.doi.org/10.1038/sj.emboj.7601049.
26. Albitar L, Pickett G, Morgan M, Davies S, Leslie KK. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol 2007; 106:52-64; PMID:17490735; http://dx.doi.org/10.1016/j.ygyno. 2007.02.033.
27. Halmy L, Fehér T, Steczek K, Farkas A. High serum bile acid level in obesity: its decrease during and after total fasting. Acta Med Hung 1986; 43:55-8; PMID:3774418.
28. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147:545-60; PMID:7677168.
29. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25:1620-8; PMID:16550162; http://dx.doi.org/10.1038/sj.onc.1209371.
30. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011; 10:57-67; PMID:21200143; http://dx.doi.org/10.4161/cc.10.1.14449.
31. Arnold A, Kim HG, Gaz RD, Eddy RL, Fukushima Y, Byers MG, et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989; 83:2034-40; PMID:2723071; http://dx.doi.org/10.1172/JCI114114.
32. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991; 11:4846-53; PMID:1833629.
33. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68:67-108; PMID:8712071; http://dx.doi.org/10.1016/S0065-230X(08)60352-8.
34. Caldon CE, Sutherland RL, Musgrove E. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 2010; 9:1918-28; PMID:20473028; http://dx.doi.org/10.4161/cc.9.10.11474.
35. Ruhul Quddus M, Latkovich P, Castellani WJ, James Sung C, Steinhoff MM, Briggs RC, et al. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 2002; 126:459-63; PMID:11900573.
36. Catalano S, Giordano C, Rizza P, Gu G, Barone I, Bonofiglio D, et al. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol 2009; 218:490-500; PMID:18988190; http://dx.doi.org/10.1002/jcp.21622.
37. Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 2010; 78:617-30; PMID:20631053; http://dx.doi.org/10.1124/mol.110.064501.